静脉溶栓联合药物治疗轻度缺血性脑卒中的疗效观察

中国基层医药 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.05.012

Gang Lou, L. Chi, Weili Chen, Zhenxiao Chai, K. Xia, Chao-quan Wu

{"title":"静脉溶栓联合药物治疗轻度缺血性脑卒中的疗效观察","authors":"Gang Lou, L. Chi, Weili Chen, Zhenxiao Chai, K. Xia, Chao-quan Wu","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.012","DOIUrl":null,"url":null,"abstract":"Objective \nTo explore the effect of dual antiplatelet combined with calf serum deproteinized injection in the treatment of mild ischemic stroke after intravenous thrombolysis. \n \n \nMethods \nFrom October 2017 to December 2018, 82 patients with mild ischemic stroke who were diagnosed in the People's Hospital of Ruian were selected.The patients were divided into control group (41 cases) and observation group (41 cases) according to random number table method.The control group was treated with aspirin after intravenous thrombolysis.On this basis, the observation group was treated with dual antiplatelet combined with calf serum deproteinized injection.The course of treatment was 3 months in both two groups.The total effective rate, the changes of hemorheological indicators, the improvement of neurological deficit, the ability of daily living and the ability of returning to society were compared between the two groups before and after treatment.The complications and prognosis were recorded. \n \n \nResults \nThe total effective rate of the observation group was 95.12% (39/41), which was higher than 78.05% (32/41) of the control group (χ2=5.145, P 0.05). \n \n \nConclusion \nAfter intravenous thrombolytic therapy for patients with mild ischemic stroke, dual antiplatelet therapy combined with calf serum deproteinized injection can improve the neurological function, life ability and hemorheological indicators of patients, with good prognosis, it is safe and effective. \n \n \nKey words: \nStroke; Thrombolytic therapy; Aspirin; Platelet aggregation inhibitors; Calf serum deproteinized injection; Drug therapy, combination; Hemorheology; Prognosis","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 1","pages":"563-567"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Therapeutic effect of intravenous thrombolysis combined with drug therapy on mild ischemic stroke\",\"authors\":\"Gang Lou, L. Chi, Weili Chen, Zhenxiao Chai, K. Xia, Chao-quan Wu\",\"doi\":\"10.3760/CMA.J.ISSN.1008-6706.2020.05.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective \\nTo explore the effect of dual antiplatelet combined with calf serum deproteinized injection in the treatment of mild ischemic stroke after intravenous thrombolysis. \\n \\n \\nMethods \\nFrom October 2017 to December 2018, 82 patients with mild ischemic stroke who were diagnosed in the People's Hospital of Ruian were selected.The patients were divided into control group (41 cases) and observation group (41 cases) according to random number table method.The control group was treated with aspirin after intravenous thrombolysis.On this basis, the observation group was treated with dual antiplatelet combined with calf serum deproteinized injection.The course of treatment was 3 months in both two groups.The total effective rate, the changes of hemorheological indicators, the improvement of neurological deficit, the ability of daily living and the ability of returning to society were compared between the two groups before and after treatment.The complications and prognosis were recorded. \\n \\n \\nResults \\nThe total effective rate of the observation group was 95.12% (39/41), which was higher than 78.05% (32/41) of the control group (χ2=5.145, P 0.05). \\n \\n \\nConclusion \\nAfter intravenous thrombolytic therapy for patients with mild ischemic stroke, dual antiplatelet therapy combined with calf serum deproteinized injection can improve the neurological function, life ability and hemorheological indicators of patients, with good prognosis, it is safe and effective. \\n \\n \\nKey words: \\nStroke; Thrombolytic therapy; Aspirin; Platelet aggregation inhibitors; Calf serum deproteinized injection; Drug therapy, combination; Hemorheology; Prognosis\",\"PeriodicalId\":10226,\"journal\":{\"name\":\"中国基层医药\",\"volume\":\"27 1\",\"pages\":\"563-567\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中国基层医药\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

目的探讨双抗血小板联合小牛血清去蛋白注射液治疗轻度缺血性脑卒中静脉溶栓后的疗效。方法选取2017年10月~ 2018年12月在瑞安市人民医院确诊的轻度缺血性脑卒中患者82例。采用随机数字表法将患者分为对照组(41例)和观察组(41例)。对照组患者静脉溶栓后给予阿司匹林治疗。在此基础上，观察组患者给予双抗血小板联合小牛血清去蛋白注射液治疗。两组疗程均为3个月。比较两组患者治疗前后总有效率、血液流变学指标变化情况、神经功能缺损改善情况、日常生活能力及重返社会能力。记录并发症及预后。结果观察组总有效率为95.12%(39/41)，高于对照组78.05% (32/41)(χ2=5.145, p0.05)。结论轻度缺血性脑卒中患者经静脉溶栓治疗后，双重抗血小板治疗联合小牛血清去蛋白注射液可改善患者神经功能、生活能力和血液流变学指标，预后良好，安全有效。关键词:卒中;溶栓治疗;阿斯匹林;血小板聚集抑制剂;小牛血清去蛋白注射液;药物治疗、联合用药;血液流变学;预后

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Therapeutic effect of intravenous thrombolysis combined with drug therapy on mild ischemic stroke

Objective To explore the effect of dual antiplatelet combined with calf serum deproteinized injection in the treatment of mild ischemic stroke after intravenous thrombolysis. Methods From October 2017 to December 2018, 82 patients with mild ischemic stroke who were diagnosed in the People's Hospital of Ruian were selected.The patients were divided into control group (41 cases) and observation group (41 cases) according to random number table method.The control group was treated with aspirin after intravenous thrombolysis.On this basis, the observation group was treated with dual antiplatelet combined with calf serum deproteinized injection.The course of treatment was 3 months in both two groups.The total effective rate, the changes of hemorheological indicators, the improvement of neurological deficit, the ability of daily living and the ability of returning to society were compared between the two groups before and after treatment.The complications and prognosis were recorded. Results The total effective rate of the observation group was 95.12% (39/41), which was higher than 78.05% (32/41) of the control group (χ2=5.145, P 0.05). Conclusion After intravenous thrombolytic therapy for patients with mild ischemic stroke, dual antiplatelet therapy combined with calf serum deproteinized injection can improve the neurological function, life ability and hemorheological indicators of patients, with good prognosis, it is safe and effective. Key words: Stroke; Thrombolytic therapy; Aspirin; Platelet aggregation inhibitors; Calf serum deproteinized injection; Drug therapy, combination; Hemorheology; Prognosis

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.